The overall safety profile of currently available vaccines directed against infectious diseases

Expert Opinion on Drug Safety

Volumn 2, Issue 3, 2003, Pages 215-223

  Jacobson, Robert M ^a   Zabel, Kim S ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

contraindications; records; registries; safety; safety management; vaccination; vaccination adverse effects; vaccines; vaccines adverse effects

Indexed keywords

VACCINE;

COMMUNICABLE DISEASE; HUMAN; IMMUNOLOGY; INFECTION CONTROL; REVIEW;

COMMUNICABLE DISEASES; HUMANS; INFECTION CONTROL; VACCINES;

EID: 0141818269     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.3.215     Document Type: Review

References (65)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION: Ten great public health achievements-United States, 1900-1999. MMWR (1999) 48:241-243.
2. CENTERS FOR DISEASE CONTROL AND PREVENTION: Vaccine Safety. Public Health Foundation, Waldorf, MD (2002):218-241.
3. SILVERS LE, ELLENBERG SS, WISE RP, VARRICCHIO FE, MOOTREY GT, SALIVE ME: The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997. Pharmacoepidemiol. Drug Saf. (2001) 10:279-285. (Pubitemid 33040844)
4. SILVERS LE, VARRICCHIO FE, ELLENBERG SS, KRUEGER CL, WISE RP, SALIVE ME: Pediatric deaths reported after vaccination: the utility of information obtained from parents. Am. J. Prev. Med. (2002) 22:170-176. (Pubitemid 34207823)
5. GRIFFIN M, RAY W, LIVENGOOD J, SCHAFFNER W: Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N. Engl. J. Med. (1988) 319:618-623.
6. ESSERY S, RAZA M, ZORGANI A et al.: The protective effect of immunisation against diphtheria, pertussis and tetanus (DPT) in relation to sudden infant death syndrome. FEMS Immunol. Med. Microbiol. (1999) 25:183-192. (Pubitemid 29317572)
7. NIU M, SALIVE M, ELLENBERG S: Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998. Arch. Pediatr. Adolesc. Med. (1999) 153:1279-1282.
8. JONVILLE-BERA A, AUTRET-LECA E, BARBEILLON F, PARIS-LLADO J: Sudden unexpected death in infants under 3 months of age and vaccination status-a case-control study. Br. J. Clin. Pharmacol. (2001) 51:271-276. (Pubitemid 32391504)
9. INSTITUTE OF MEDICINE: Adverse Events Associated with Childhood Vaccines. National Academy Press, Washington, DC (1994).
10. CHEN RT, DESTEFANO F, PLESS R, MOOTREY G, KRAMARZ P, HIBBS B: Challenges and controversies in immunization safety. Infect. Dis. Clin. North Am. (2001) 15:21-39. (Pubitemid 32268112)
11. MCDONNELL WM, ASKARI FK: Immunization. JAMA (1997) 278:2000-2007. (Pubitemid 28007275)
12. ELLENBERG S: Safety considerations for new vaccine development. Pharmacoepidemiol. Drug Saf. (2001) 10:411-415. (Pubitemid 33138464)
13. DITTMANN S: Vaccine safety: risk communication-a global perspective. Vaccine (2001) 19:2446-2456. (Pubitemid 32234256)
14. ADA G: Advances in immunology: vaccines and vaccination. N. Engl. J. Med. (2001) 345:1042-1053.
15. ZHOU W, POOL V, ISKANDER JK et al.: Surveillance for safety after immunization: Vaccine Event Report System (VAERS)-United States, 1991-2001. MMWR (2003) 52:1-24.
16. BRAUN MM, PATRIARCA PA, ELLENBERG SS: Syncope after immunization. Arch. Pediatr. Adolesc. Med. (1997) 151:255-259. (Pubitemid 27133207)
17. ANONYMOUS: Anaphylaxis: statement on initial management in nonhospital settings. Can. Med. Assoc. J. (1996) 154:1519-1522.
18. CENTERS FOR DISEASE CONTROL AND PREVENTION: Update: vaccine side effects, adverse reactions, contraindications, and precautions-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (1996) 45(RR-12):1-35.
19. GEORGITIS JW, FASANO MB: Allergenic components of vaccines and avoidance of vaccination-related adverse events. Curr. Allergy Rep. (2001) 1:11-17.
20. POOL V, BRAUN MM, KELSO JM et al.: Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics (2002) 110:e71.
21. AMERICAN ACADEMY OF PEDIATRICS: Active Immunization. Pickering LK (Ed.), American Academy of Pediatrics, Elk Grove Village, IL (2000).
22. OVENS H: Anaphylaxis due to vaccination in the office. Can. Med. Assoc. J. (1986) 134:369-370.
23. US DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS, CENTERS FOR DISEASE CONTROL AND PREVENTION: Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation: a report of the National Vaccine Advisory Committee. MMWR (2000) 49:1-14.
24. GELLIN BG, MAIBACH EW, MARCUSE EK: Do parents understand immunizations? A national telephone survey. Pediatrics (2000) 106:1097-1102.
25. OFFIT PA, QUARLES J, GERBER MA et al.: Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics (2002) 110:648-649.
26. ENGLUND JA, SUAREZ CS, KELLY J, TATE DY, BALFOUR HH Jr: Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J. Pediatr. (1989) 114:37-44. (Pubitemid 19027737)
27. BRUNELL PA, NOVELLI VM, LIPTON SV, POLLOCK B: Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics (1988) 81:779-784.
28. DEFOREST A, LONG SS, LISCHNER HW et al.: Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics (1988) 81:237-246. (Pubitemid 18060604)
29. GIAMMANCO G, LI VOLTI S, MAURO L et al.: Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine (1991) 9:747-750.
30. SHINEFIELD HR, BLACK SB, STAEHLE BO et al.: Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, Varivax and Tetramune in healthy children versus concomitant injections of M-M-R II and Tetramune followed six weeks later by Varivax. Pediatr. Infect. Dis. J. (1998) 17:980-985. (Pubitemid 28549415)
31. DASHEFSKY B, WALD E, GUERRA N, BYERS C: Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae Type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14-to 23-month-old infants. Pediatrics (1990) 85:682-689. (Pubitemid 20099536)
32. ANONYMOUS: Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR (1999) 48:563-565.
33. CLEMENTS CJ, BALL LK, BALL R, PRATT RD: Thiomersal in vaccines: is removal warranted? Drug Saf. (2001) 24:567-574. (Pubitemid 32656070)
34. STRATTON K, GABLE A, SHETTY P, MCCORMICK M: Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism Health Promotion and Disease Prevention. National Academy Press, Washington, DC (2001).
35. STRATTON K, ALMARIO DA, WIZEMANN TM, MCCORMICK MC: Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy. National Academy Press, Washington, DC (2003).
36. COMMUNICABLE DISEASE SURVEILLANCE CENTRE: COVER programme: January to March 2001. Commun. Dis. Rep. CDR Wkly. (2001) 11:6-8.
37. OWENS SR: Injection of confidence. The recent controversy in the UK has led to falling MMR vaccination rates. EMBO Rep. (2002) 3:406-409. (Pubitemid 34567425)
38. SPOONER MH: Measles outbreaks in UK linked to fears about MMR vaccine. Can. Med. Assoc. J. (2002) 166:1075.
39. POLAND GA, JACOBSON RM: Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine (2001) 19:2440-2445. (Pubitemid 32234255)
40. POLAND GA, JACOBSON RM: Vaccine safety: injecting a dose of common sense. Mayo Clin. Proc. (2000) 75:135-139. (Pubitemid 30080702)
41. GELLIN BG, SCHAFFNER W: The risk of vaccination-the importance of 'negative' studies. N. Engl. J. Med. (2001) 344:372-373. (Pubitemid 32107647)
42. ANONYMOUS: Vaccines-endangered species? Nat. Immunol. (2002) 3:695.
43. CHEN R: Vaccine risks: real, perceived and unknown. Vaccine (1999) 17(Suppl. 3):S41-S46. (Pubitemid 29516679)
44. PARKMAN PD: Making vaccination policy: the experience with rubella. Clin. Infect. Dis. (1999) 28(Suppl. 2):S140-S146. (Pubitemid 29270384)
45. JACOBSON RM, ADEGBENRO A, PANKRATZ VS, POLAND GA: Adverse events and vaccination-the lack of power and predictability of infrequent events in prelicensure study. Vaccine (2001) 19:2428-2433. (Pubitemid 32234253)
46. ELLENBERG SS, BRAUN MM: Monitoring the safety of vaccines: assessing the risks. Drug Saf. (2002) 25:145-152. (Pubitemid 34492935)
47. BLACK S: Perspectives on the design and analysis of prelicensure trials: bridging the gap to postlicensure studies. Clin. Infect. Dis. (2001) 33(Suppl. 4):S323-S326. (Pubitemid 33152378)
48. DESTEFANO F AND THE VACCINE SAFETY DATALINK RESEARCH GROUP: The Vaccine Safety Datalink project. Pharmacoepidemiol. Drug Saf. (2001) 10:403-406.
49. CLARKSON A, INGLEBY E, CHOONARA I, BRYAN P, ARLETT P: A novel scheme for the reporting of adverse drug reactions. Arch. Dis. Child. (2001) 84:337-339. (Pubitemid 32328630)
50. RENNELS MB: The rotavirus vaccine story: a clinical investigator's view. Pediatrics (2000) 106:123-125. (Pubitemid 30436884)
51. CENTERS FOR DISEASE CONTROL AND PREVENTION: Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (1999) 48:1-20.
52. HARRIS G: After vaccine's recall, regulators look for holes in the safety net. Wall St. J. (1999):B1,B4.
53. CENTERS FOR DISEASE CONTROL AND PREVENTION: Withdrawal of rotavirus vaccine recommendation. MMWR (1999) 48:1007.
54. GOLD M, GOODWIN H, BOTHAM S, BURGESS M, NASH M, KEMPE A: Revaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service. Arch. Dis. Child. (2000) 83:128-131. (Pubitemid 30670421)
55. ANONYMOUS: Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR (1993) 42(RR-4):1-18.
56. DAVIS T, FREDRICKSON D, ARNOLD C et al.: Childhood vaccine risk/benefit communication in private practice office settings: a national survey. Pediatrics (2001) 107:E17.
57. US DEPARTMENT OF HEALTH AND HUMAN SERVICES: Immunization and Infectious Diseases. US Government Printing Office, Washington, DC (2000):14-42.
58. YAWN BP, GAZZUOLA L, WOLLAN PC, KIM WR: Development and maintenance of a community-based hepatitis C registry. Am. J. Manage. Care (2002) 8:253-261. (Pubitemid 34256635)
59. HEIJBEL H, JEFFERSON T: Vaccine safety-improving monitoring. Vaccine (2001) 19:2457-2460.
60. YAWN BP, EDMONSON L, HUBER L, POLAND GA, JACOBSON RM, JACOBSEN SJ: The impact of a simulated immunization registry on perceived childhood immunization status. Am. J. Manage. Care (1998) 4:185-192. (Pubitemid 28420173)
61. WOLFE S: Vaccine information statements in the pediatric office. Pediatr. Ann. (2001) 30:416-417. (Pubitemid 32642540)
62. JACOBSON RM, ZABEL KS, POLAND GA: The challenge of vaccine safety. Semin. Pediatr. Infect. Dis. (2002) 13:215-220.
63. POLAND GA, MURRAY D, BONILLA-GUERRERO R: Science, medicine, and the future: new vaccine development. Br. Med. J. (2002) 324:1315-1319. (Pubitemid 34606776)
64. ANDRÉ FE: The future of vaccines, immunisation concepts and practice. Vaccine (2001) 19:2206-2209. (Pubitemid 32234214)
65. US DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS, CENTERS FOR DISEASE CONTROL AND PREVENTION: Guide to contraindications to childhood vaccinations, 2000 (2000). Report.